{
  "docId": "019de076-4b6e-745e-b621-2097373bdc12",
  "docSlug": "454a033dcd11e0912fc4b281c3c86d65",
  "documentTitle": "Innoviva | Results Presentation Deck | 7 slides",
  "authorId": "innoviva",
  "authorName": "Innoviva",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 7,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The diagram illustrates a randomized controlled trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4b6e-745e-b621-2097373bdc12/3",
  "deckHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12",
  "deckJsonHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12.json",
  "deckAnchorHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.4,
        "x": 0.55,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Flowchart showing patient enrollment, 2:1 randomization, treatment arms, and analysis endpoints.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8262bfa-1b4d-4d8f-8b9e-c4aa760c99ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.09,
        "y": 0.41
      },
      "kind": "paragraph",
      "text": "The primary efficacy endpoint was microbiological test of cure at urethral or cervical sites (urogenital) in participants who had a positive culture for gonorrhea at baseline.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5474d998-33a8-450b-8932-81cfa563f136",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.09,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "Secondary analyses were microbiological cure at rectal or pharyngeal sites and safety. The trial was designed with a 90% power and a 10% noninferiority margin.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7520d39b-f9f9-48bb-a773-779cfdf11a8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.09,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "This was a global study, conducted at 16 sites in the United States, South Africa, Belgium, Netherlands, and Thailand.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "940ab1ac-226e-44b7-852d-18b7aad7f1bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.09,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "The zoliflodacin pivotal Phase 3 registration trial was conducted to evaluate the efficacy of a single 3g oral dose of zoliflodacin in treatment of uncomplicated gonorrhea compared to treatment with intramuscular injection of ceftriaxone and oral azithromycin, a current global standard of care regimen.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0b90e65-9e52-43d6-b89c-c6d436fb4ee2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Abbreviations: CRO-AZI – ceftriaxone and azithromycin; IM – intramuscular injection",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47fb06ac-703e-4796-8cc4-f4fe31102d86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Zoliflodacin Phase 3 registration study design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85fe7de6-b540-46ac-ad00-22a3f42ff9bd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "76f154b0-3107-41f8-be3a-625577cd64c0",
      "evidence": "Flowchart depicting the clinical trial study design steps.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 7,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cc60ccb3-7bfb-482b-bd2f-71df33588aa9",
      "evidence": "Implication of antibiotic resistance and need for new treatments",
      "position": 0,
      "objective": "What are the consequences of not adopting Zoliflodacin?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}